Sarah Arron


Dermatologic surgeon
Coffee lover, cancer researcher and textile artist

About me

Dr. Sarah Arron is a dermatologic surgeon who specializes in Mohs micrographic surgery, an advanced procedure used to treat certain skin cancers. Her expertise encompasses skin cancer, facial reconstruction following surgery, and dermatology for organ transplant recipients and patients who have genetic cancer syndromes. She also performs laser surgery and cosmetic procedures, including use of Botox and soft tissue fillers.

Arron earned her medical degree at Weill Cornell Medicine. She earned a doctorate in biomedical science at the Rockefeller University. She completed a residency in dermatology and a fellowship in Mohs micrographic surgery and procedural dermatology at UCSF.

Arron is passionate about fostering innovation in dermatology. Her research laboratory focuses on sophisticated genetic investigations of squamous cell skin cancer and skin viruses. She directs UCSF's Dermatology Clinical Research Unit, and she has been the principal investigator on a number of important clinical trials. Arron serves as a consultant for startup companies in the dermatology industry and advises pharmaceutical companies in the areas of skin care, inflammatory skin disease and skin cancer.

  • Education

    The Rockefeller University, PhD, Biomedical Sciences, 2002

    Weill Cornell Medicine, 2003

  • Residencies

    UCSF, Dermatology, 2008

  • Fellowship

    UCSF, Procedural Dermatology, 2007

  • Academic Title

    Associate Professor

Dermatologic Surgery and Laser Center

1701 Divisadero St.
San Francisco, CA 94115

High-Risk Skin Cancer Clinic

1701 Divisadero St., Third Floor
San Francisco, CA 94143-0316

Melanoma & Skin Cancer Program

Bakar Precision Cancer Medicine Building

1825 Fourth Street, Third Floor
San Francisco, CA 94158

Selected research

Decorative Caduceus

PF-06651600 for the Treatment of Alopecia Areata

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss....